Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | HTR1D | P28221 | 3/20 | 0.32 |
| ▸ | HTR1B | P28222 | 3/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124781 | 0.92 | ACHE (0.33) | CCR9CCR2MCL1HTR1AHTR1D | |
| SCHEMBL5124540 | 0.92 | CHRM5 (0.36) | CCR2TNKSPARP1TNKS2MCL1 | |
| SCHEMBL5125545 | 0.91 | TMEM97 (0.36) | CCR2TNKSPARP1TNKS2MCL1 | |
| SCHEMBL5114026 | 0.88 | MET (0.37) | CCR2MCL1KDM4EALDH1A1MEN1 | |
| SCHEMBL5119462 | 0.84 | MAPK14 (0.39) | MCL1PTK2ALDH1A1HSD17B10ACHE | |
| SCHEMBL5110189 | 0.84 | RECQL (0.37) | MCL1HTR1BPTK2KDM4EALDH1A1 | |
| SCHEMBL5110935 | 0.83 | HRH3 (0.35) | MCL1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL5119338 | 0.82 | KDM4E (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL5118314 | 0.80 | KDM4E (0.38) | MCL1KDM4EHSD17B10MEN1POLB | |
| SCHEMBL5111119 | 0.80 | MCL1 (0.36) | CCR9CCR2MCL1PTK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| US-7078419-B2 | N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235017-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1R1 | CCR9 112/4885CCR2 256/4885TNKS 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.